|
1
|
Girardi FM, Barra MB and Zettler CG:
Analysis of pattern of occurrence of thyroid carcinoma between 2001
and 2010. Braz J Otorhinolaryngol. 81:541–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hay ID, Thompson GB, Grant CS, Bergstralh
EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL,
et al: Papillary thyroid carcinoma managed at the Mayo Clinic
during six decades (1940–1999): Temporal trends in initial therapy
and long-term outcome in 2444 consecutively treated patients. World
J Surg. 26:879–885. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forbes SA, Bindal N, Bamford S, Cole C,
Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, et al:
COSMIC: Mining complete cancer genomes in the catalogue of somatic
mutations in cancer. Nucleic Acids Res. 39(Database): D945–D950.
2011. View Article : Google Scholar :
|
|
4
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dees ND, Zhang Q, Kandoth C, Wendl MC,
Schierding W, Koboldt DC, Mooney TB, Callaway MB, Dooling D, Mardis
ER, et al: MuSiC: Identifying mutational significance in cancer
genomes. Genome Res. 22:1589–1598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer T and Atlas G; Cancer Genome Atlas
Research Network: Integrated genomic characterization of papillary
thyroid carcinoma. Cell. 159:676–690. 2014. View Article : Google Scholar
|
|
7
|
Wood LD, Parsons DW, Jones S, Lin J,
Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al: The
genomic landscapes of human breast and colorectal cancers. Science.
318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gonzalez-Perez A and Lopez-Bigas N:
Functional impact bias reveals cancer drivers. Nucleic Acids Res.
40:e1692012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ng PC and Henikoff S: SIFT: Predicting
amino acid changes that affect protein function. Nucleic Acids Res.
31:3812–3814. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adzhubei IA, Schmidt S, Peshkin L,
Ramensky VE, Gerasimova A, Bork P, Kondrashov AS and Sunyaev SR: A
method and server for predicting damaging missense mutations. Nat
Methods. 7:248–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reva B, Antipin Y and Sander C: Predicting
the functional impact of protein mutations: Application to cancer
genomics. Nucleic Acids Res. 39:e1182011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vandin F, Upfal E and Raphael BJ: De novo
discovery of mutated driver pathways in cancer. Genome Res.
22:375–385. 2012. View Article : Google Scholar :
|
|
13
|
McLaren W, Pritchard B, Rios D, Chen Y,
Flicek P and Cunningham F: Deriving the consequences of genomic
variants with the Ensembl API and SNP effect predictor.
Bioinformatics. 26:2069–2070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al The Gene Ontology Consortium: Gene ontology: Tool for the
unification of biology. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Costa V, Esposito R, Ziviello C, Sepe R,
Bim LV, Cacciola NA, Decaussin-Petrucci M, Pallante P, Fusco A and
Ciccodicola A: New somatic mutations and WNK1-B4GALNT3 gene fusion
in papillary thyroid carcinoma. Oncotarget. 6:11242–11251. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim D, Pertea G, Trapnell C, Pimentel H,
Kelley R and Salzberg SL: TopHat2: Accurate alignment of
transcriptomes in the presence of insertions, deletions and gene
fusions. Genome Biol. 14:R362013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Quinlan AR and Hall IM: BEDTools: A
flexible suite of utilities for comparing genomic features.
Bioinformatics. 26:841–842. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lawrence MS, Stojanov P, Mermel CH,
Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander
ES and Getz G: Discovery and saturation analysis of cancer genes
across 21 tumour types. Nature. 505:495–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhong Q, Peng H-L, Zhao X, Zhang L and
Hwang W-T: Effects of BRCA1/2 on ovarian and breast cancer
survival-response. Clin Cancer Res. 21:3807. 2015. View Article : Google Scholar
|
|
21
|
Fujimoto A, Totoki Y, Abe T, Boroevich KA,
Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al:
Whole-genome sequencing of liver cancers identifies etiological
influences on mutation patterns and recurrent mutations in
chromatin regulators. Nat Genet. 44:760–764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Golding SE, Rosenberg E, Adams BR,
Wignarajah S, Beckta JM, O'Connor MJ and Valerie K: Dynamic
inhibition of ATM kinase provides a strategy for glioblastoma
multiforme radiosensiti-zation and growth control. Cell Cycle.
11:1167–1173. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Negi SS and Brown P: rRNA synthesis
inhibitor, CX-5461, activates ATM/ATR pathway in acute
lymphoblastic leukemia, arrests cells in G2 phase and induces
apoptosis. Oncotarget. 6:18094–18104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bentires-Alj M, Paez JG, David FS,
Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A,
Sugarbaker DJ, et al: Activating mutations of the noonan
syndrome-associated SHP2/PTPN11 gene in human solid tumors and
adult acute myelogenous leukemia. Cancer Res. 64:8816–8820. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Seki M, Yoshida K, Shiraishi Y, Shimamura
T, Sato Y, Nishimura R, Okuno Y, Chiba K, Tanaka H, Kato K, et al:
Biallelic DICER1 mutations in sporadic pleuropulmonary blastoma.
Cancer Res. 74:2742–2749. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hasan R, Sharma R, Saraya A, Chattopadhyay
TK, DattaGupta S, Walfish PG, Chauhan SS and Ralhan R: Mitogen
activated protein kinase kinase kinase 3 (MAP3K3/MEKK3)
overexpression is an early event in esophageal tumorigenesis and is
a predictor of poor disease prognosis. BMC Cancer. 14:22014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Samanta AK, Huang HJ, Bast RC Jr and Liao
WS-L: Overexpression of MEKK3 confers resistance to apoptosis
through activation of NFkappaB. J Biol Chem. 279:7576–7583. 2004.
View Article : Google Scholar
|
|
29
|
Arndt S and Bosserhoff AK: Reduced
expression of TANGO in colon and hepatocellular carcinomas. Oncol
Rep. 18:885–891. 2007.PubMed/NCBI
|
|
30
|
Arndt S and Bosserhoff AK: TANGO is a
tumor suppressor of malignant melanoma. Int J Cancer.
119:2812–2820. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gonzalo S: Epigenetic alterations in
aging. J Appl Physiol. 1985(109): 586–597. 2010. View Article : Google Scholar
|
|
32
|
Xing M, Alzahrani AS, Carson KA, Shong YK,
Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, et al:
Association between BRAF V600E mutation and recurrence of papillary
thyroid cancer. J Clin Oncol. 33:42–50. 2015. View Article : Google Scholar
|
|
33
|
Inumaru JS, Gordo KI, Fraga Junior AC,
Silva AM, Leal CB, Ayres FM, Wastowski IJ, Borges NF and Saddi VA:
Analysis of the BRAF V600E mutation in primary cutaneous melanoma.
Genet Mol Res. 13:2840–2848. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Parikh C, Subrahmanyam R and Ren R:
Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic
potentials in mice. Cancer Res. 67:7139–7146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang C, Chen Y, Wang M, Chen X, Li Y,
Song E, Liu X, Kim S and Peng H: PPM1D silencing by RNA
interference inhibits the proliferation of lung cancer cells. World
J Surg Oncol. 12:2582014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ruark E, Snape K, Humburg P, Loveday C,
Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, et
al Breast and Ovarian Cancer Susceptibility Collaboration: Wellcome
Trust Case Control Consortium: Mosaic PPM1D mutations are
associated with predisposition to breast and ovarian cancer.
Nature. 93:406–410. 2013.
|
|
37
|
Brabender J, Danenberg KD, Metzger R,
Schneider PM, Lord RV, Groshen S, Tsao-Wei DD, Park J, Salonga D,
Hölscher AH, et al: The role of retinoid X receptor messenger RNA
expression in curatively resected non-small cell lung cancer. Clin
Cancer Res. 8:438–443. 2002.PubMed/NCBI
|
|
38
|
Papi A, Rocchi P, Ferreri AM and Orlandi
M: RXRgamma and PPARgamma ligands in combination to inhibit
proliferation and invasiveness in colon cancer cells. Cancer Lett.
297:65–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu Z, Zhou G, Nakamura M, Bai Y, Li Y,
Ozaki T, Mori I, Miyauchi A and Kakudo K: Retinoid X receptor γ
up-regulation is correlated with dedifferentiation of tumor cells
and lymph node metastasis in papillary thyroid carcinoma. Pathol
Int. 61:109–115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Klopper JP, Hays WR, Sharma V, Baumbusch
MA, Hershman JM and Haugen BR: Retinoid X receptor-gamma and
peroxisome proliferator-activated receptor-gamma expression
predicts thyroid carcinoma cell response to retinoid and
thiazolidinedione treatment. Mol Cancer Ther. 3:1011–1020.
2004.PubMed/NCBI
|
|
41
|
Szekeres K, Koul R, Mauro J, Lloyd M,
Johnson J and Blanck G: An Oct-1-based, feed-forward mechanism of
apoptosis inhibited by co-culture with Raji B-cells: Towards a
model of the cancer cell/B-cell microenvironment. Exp Mol Pathol.
97:585–589. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sellar GC, Watt KP, Rabiasz GJ, Stronach
EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B,
Scott D, et al: OPCML at 11q25 is epigenetically inactivated and
has tumor-suppressor function in epithelial ovarian cancer. Nat
Genet. 34:337–343. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fan S, Meng D, Xu T, Chen Y, Wang J, Li X,
Chen H, Lu D, Chen J and Lan Q: Overexpression of SLC7A7 predicts
poor progression-free and overall survival in patients with
glio-blastoma. Med Oncol. 30:3842013. View Article : Google Scholar
|
|
44
|
Fan S, Zhao Y, Li X, Du Y, Wang J, Song X,
Zhou F, Chen H, Chen G, Zhao Y, et al: Genetic variants in SLC7A7
are associated with risk of glioma in a Chinese population. Exp
Biol Med (Maywood). 238:1075–1081. 2013. View Article : Google Scholar
|
